ASPREE News

The ASPREE (ASPirin in Reducing Events in the Elderly) study team celebrated reaching 12,000 Australian participants recently.  The study is testing if 100mg of daily aspirin prevents or delays heart attack, stroke, dementia and some malignancies in otherwise healthy people aged >70 years. The placebo-controlled clinical trial will weigh the benefits of aspirin against the risks.  ASPREE is primarily undertaken at metropolitan and regional GP clinics in the south eastern Australia and employs almost 100 full time and part time staff.

The same week, the ASPREE Healthy Ageing Biobank team marked the 8000^th participant in the study with delicious cake (see pic). Biobank research assistants travel extensively throughout Victoria, Southern NSW, Tasmania and Southern SA, collecting and preparing blood samples for long term storage in the Healthy Ageing Biobank.

The ASPREE and Biobank teams would like to sincerely thank GPs and older Australians for supporting clinical research into health ageing. The studies aim to reach 16,000 ASPREE and 10,000 Healthy Ageing Biobank participants.